{
  "id": 20254843,
  "title": "A drug does not treat a virtual model. It treats a real patient",
  "url": "https://urgent.news/2026/11/16/a-drug-does-not-treat-a-virtual-model-it-treats-a-real-patient",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T02:00:15.000Z",
  "source": {
    "name": "e27",
    "slug": "e27",
    "url": "https://e27.co/a-drug-does-not-treat-a-virtual-model-it-treats-a-real-patient-20261111/"
  },
  "original_language": "en",
  "account": "Artificial intelligence is altering how pharmaceutical companies assess potential medicines, forecast results, and evaluate risks during clinical trials. Computer simulations assist researchers in exploring options before a treatment reaches patients. These predictive models can uncover patterns that might otherwise be challenging to identify. However, an important question remains unanswered: how accurately do these predictions mirror the real-life clinical experiences of the patients who will ultimately use the treatment?\n\nA patient is not merely a collection of disease markers. Their medical history, concurrent health conditions, additional medications, unique risk factors, and other clinical details can impact the effectiveness and safety of treatment. Additionally, these factors can determine whether a drug will succeed and advance to subsequent trial phases. This is where I believe incorporating patient-specific clinical context may significantly influence outcomes.\n\nVirtual simulations prove valuable because they enable researchers to model potential outcomes based on predefined assumptions. They facilitate the exploration of scenarios, testing of hypotheses, and comprehension of how modifying specific variables might affect results. However, their effectiveness relies on the assumptions, data, and parameters utilized in their construction. If a crucial clinical factor is absent, incomplete, or insufficiently represented within the model, the simulation may overlook its potential impact. This does not render virtual simulations ineffective; rather, it emphasizes the necessity of comprehending their limitations.\n\nClinical development inherently involves uncertainty. Success in preclinical animal studies does not guarantee successful outcomes in humans, and results observed across a clinical trial cohort may not consistently translate to every individual patient. Even a drug that achieves early-phase trial success, supported by promising human data, can still fail in later-stage trials when evaluated in larger or more diverse populations or against more stringent clinical endpoints.\n\nExamining a patient's clinical context within the equation\nLet's consider a hypothetical scenario. A patient is being evaluated for a clinical trial. Their primary diagnosis and disease severity align with the study population. A general model might suggest that the treatment's expected benefits and risks are comparable to those of similar patients. However, the patient also has additional medical conditions and takes multiple concomitant medications. These factors may introduce safety concerns, potential drug-drug interactions, or questions necessitating further clinical review.\n\nThis distinction is crucial: a generalized model can estimate possibilities, while an assessment based on individual clinical context can help determine whether those possibilities remain relevant when applied to a specific patient.\n\nOur approach at ClinSync does not involve replicating virtual patient simulations or serving as a drug-drug interaction checker. These represent distinct approaches and tools with separate purposes. Instead, we concentrate on the actual clinical information relevant to clinical-trial assessment: the data that could impact a patient's eligibility, potential risks, and uncertainties.\n\nThe importance of this distinction lies in the fact that merely possessing a simulation or a separate interaction-checking tool does not guarantee that every relevant aspect of an individual patient's clinical circumstances has been considered in the decision-making process. The goal is not merely to generate another AI prediction. Can AI predict a pharmaceutical company's billion-dollar clinical trial's failure? This area where AI can be helpful, but the quality of the output matters more than the technology's impressive appearance on paper.\n\nHuman verification is essential when AI predictions introduce potential issues. An AI system may misinterpret information or produce an answer that appears reasonable but lacks support from the available evidence. Expert review remains crucial, particularly in pharmacovigilance-related assessments where qualified professionals, such as a Qualified Person Responsible for Pharmacovigilance (QPPV), ensure appropriate oversight. They are not merely approving AI-generated answers; their role involves evaluating evidence, interpreting risks, and ensuring conclusions align with the context. The World Health Organisation has also emphasized the importance of human autonomy, accountability, and responsible AI use in healthcare guidelines.\n\nWhen predicting clinical trial success, it's essential to distinguish between patient-level risk assessments and predicting the overall trial's success. A hypothesis serves as the starting point, but real-world application must demonstrate that it works safely and reliably. This necessitates rigorous clinical validation and regulatory approval for healthcare AI intended for clinical use. Virtual simulations and other AI platforms that do not directly inform individual patient care may not require such extensive validation.\n\nUltimately, I do not believe the future of clinical development should focus on replacing existing models with new AI systems. Virtual simulations, clinical data, and statistical analyses will continue to play vital roles. The future depends more on understanding patients and their unique clinical contexts, rather than solely focusing on drugs.",
  "summary": "Artificial intelligence is changing how we evaluate medicines, predict outcomes and assess risks in clinical development. Virtual simulations can help researchers explore possibilities before a treatment reaches a patient. Predictive models can help identify patterns that might otherwise be difficult to see. But there is a question that deserves more attention: how closely do our […] The post A…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}